CAR-T Therapy in Haematological Malignancy Market - Global Outlook and Forecast 2021-2027

CAR-T Therapy in Haematological Malignancy Market - Global Outlook and Forecast 2021-2027

Report Code: KNJ687570 | No. of Pages: 104 | Category: Pharmaceuticals and Healthcare
Publisher: Market Monitor Global | Date of Publish: Apr-2021
This report contains market size and forecasts of CAR-T Therapy in Haematological Malignancy in Global, including the following market information:
Global CAR-T Therapy in Haematological Malignancy Market Revenue, 2016-2021, 2022-2027, ($ millions)
Global top five companies in 2020 (%)
The global CAR-T Therapy in Haematological Malignancy market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the CAR-T Therapy in Haematological Malignancy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global CAR-T Therapy in Haematological Malignancy Market, By Type, 2016-2021, 2022-2027 ($ millions)
Global CAR-T Therapy in Haematological Malignancy Market Segment Percentages, By Type, 2020 (%)
Allogeneic
Autologous

China CAR-T Therapy in Haematological Malignancy Market, By Application, 2016-2021, 2022-2027 ($ millions)
China CAR-T Therapy in Haematological Malignancy Market Segment Percentages, By Application, 2020 (%)
Hospitals
Cancer Research Centers
Others

Global CAR-T Therapy in Haematological Malignancy Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)
Global CAR-T Therapy in Haematological Malignancy Market Segment Percentages, By Region and Country, 2020 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Total CAR-T Therapy in Haematological Malignancy Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)
Total CAR-T Therapy in Haematological Malignancy Market Competitors Revenues Share in Global, by Players 2020 (%)
Further, the report presents profiles of competitors in the market, including the following:
Celgene (Juno Therapeutics)
Novartis
Gilead (Kite Pharma)
Pfizer
CARsgen Therapeutics
Autolus Therapeutics
Aurora BioPharma
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Collectis
Allogene Therapeutics
Celyad
1 Introduction to Research & Analysis Reports
    1.1 CAR-T Therapy in Haematological Malignancy Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global CAR-T Therapy in Haematological Malignancy Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global CAR-T Therapy in Haematological Malignancy Overall Market Size
    2.1 Global CAR-T Therapy in Haematological Malignancy Market Size: 2021 VS 2027
    2.2 Global CAR-T Therapy in Haematological Malignancy Market Size, Prospects & Forecasts: 2016-2027
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top CAR-T Therapy in Haematological Malignancy Players in Global Market
    3.2 Top Global CAR-T Therapy in Haematological Malignancy Companies Ranked by Revenue
    3.3 Global CAR-T Therapy in Haematological Malignancy Revenue by Companies
    3.4 Top 3 and Top 5 CAR-T Therapy in Haematological Malignancy Companies in Global Market, by Revenue in 2020
    3.5 Global Companies CAR-T Therapy in Haematological Malignancy Product Type
    3.6 Tier 1, Tier 2 and Tier 3 CAR-T Therapy in Haematological Malignancy Players in Global Market
        3.6.1 List of Global Tier 1 CAR-T Therapy in Haematological Malignancy Companies
        3.6.2 List of Global Tier 2 and Tier 3 CAR-T Therapy in Haematological Malignancy Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global CAR-T Therapy in Haematological Malignancy Market Size Markets, 2021 & 2027
        4.1.2 Allogeneic
        4.1.3 Autologous
    4.2 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue & Forecasts
        4.2.1 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue, 2016-2021
        4.2.2 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue, 2022-2027
        4.2.3 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global CAR-T Therapy in Haematological Malignancy Market Size, 2021 & 2027
        5.1.2 Hospitals
        5.1.3 Cancer Research Centers
        5.1.4 Others
    5.2 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue & Forecasts
        5.2.1 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue, 2016-2021
        5.2.2 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue, 2022-2027
        5.2.3 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027
6 Sights by Region
    6.1 By Region - Global CAR-T Therapy in Haematological Malignancy Market Size, 2021 & 2027
    6.2 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue & Forecasts
        6.2.1 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue, 2016-2021
        6.2.2 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue, 2022-2027
        6.2.3 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027
    6.3 North America
        6.3.1 By Country - North America CAR-T Therapy in Haematological Malignancy Revenue, 2016-2027
        6.3.2 US CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.3.3 Canada CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.3.4 Mexico CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
    6.4 Europe
        6.4.1 By Country - Europe CAR-T Therapy in Haematological Malignancy Revenue, 2016-2027
        6.4.2 Germany CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.4.3 France CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.4.4 U.K. CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.4.5 Italy CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.4.6 Russia CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.4.7 Nordic Countries CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.4.8 Benelux CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
    6.5 Asia
        6.5.1 By Region - Asia CAR-T Therapy in Haematological Malignancy Revenue, 2016-2027
        6.5.2 China CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.5.3 Japan CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.5.4 South Korea CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.5.5 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.5.6 India CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
    6.6 South America
        6.6.1 By Country - South America CAR-T Therapy in Haematological Malignancy Revenue, 2016-2027
        6.6.2 Brazil CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.6.3 Argentina CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue, 2016-2027
        6.7.2 Turkey CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.7.3 Israel CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.7.4 Saudi Arabia CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
        6.7.5 UAE CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
7 Players Profiles
    7.1 Celgene (Juno Therapeutics)
        7.1.1 Celgene (Juno Therapeutics) Corporate Summary
        7.1.2 Celgene (Juno Therapeutics) Business Overview
        7.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Major Product Offerings
        7.1.4 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
        7.1.5 Celgene (Juno Therapeutics) Key News
    7.2 Novartis
        7.2.1 Novartis Corporate Summary
        7.2.2 Novartis Business Overview
        7.2.3 Novartis CAR-T Therapy in Haematological Malignancy Major Product Offerings
        7.2.4 Novartis CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
        7.2.5 Novartis Key News
    7.3 Gilead (Kite Pharma)
        7.3.1 Gilead (Kite Pharma) Corporate Summary
        7.3.2 Gilead (Kite Pharma) Business Overview
        7.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Major Product Offerings
        7.3.4 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
        7.3.5 Gilead (Kite Pharma) Key News
    7.4 Pfizer
        7.4.1 Pfizer Corporate Summary
        7.4.2 Pfizer Business Overview
        7.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Major Product Offerings
        7.4.4 Pfizer CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
        7.4.5 Pfizer Key News
    7.5 CARsgen Therapeutics
        7.5.1 CARsgen Therapeutics Corporate Summary
        7.5.2 CARsgen Therapeutics Business Overview
        7.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
        7.5.4 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
        7.5.5 CARsgen Therapeutics Key News
    7.6 Autolus Therapeutics
        7.6.1 Autolus Therapeutics Corporate Summary
        7.6.2 Autolus Therapeutics Business Overview
        7.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
        7.6.4 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
        7.6.5 Autolus Therapeutics Key News
    7.7 Aurora BioPharma
        7.7.1 Aurora BioPharma Corporate Summary
        7.7.2 Aurora BioPharma Business Overview
        7.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Major Product Offerings
        7.4.4 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
        7.7.5 Aurora BioPharma Key News
    7.8 Sorrento Therapeutics
        7.8.1 Sorrento Therapeutics Corporate Summary
        7.8.2 Sorrento Therapeutics Business Overview
        7.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
        7.8.4 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
        7.8.5 Sorrento Therapeutics Key News
    7.9 Mustang Bio
        7.9.1 Mustang Bio Corporate Summary
        7.9.2 Mustang Bio Business Overview
        7.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Major Product Offerings
        7.9.4 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
        7.9.5 Mustang Bio Key News
    7.10 Bluebird Bio
        7.10.1 Bluebird Bio Corporate Summary
        7.10.2 Bluebird Bio Business Overview
        7.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Major Product Offerings
        7.10.4 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
        7.10.5 Bluebird Bio Key News
    7.11 Collectis
        7.11.1 Collectis Corporate Summary
        7.11.2 Collectis Business Overview
        7.11.3 Collectis CAR-T Therapy in Haematological Malignancy Major Product Offerings
        7.11.4 Collectis CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
        7.11.5 Collectis Key News
    7.12 Allogene Therapeutics
        7.12.1 Allogene Therapeutics Corporate Summary
        7.12.2 Allogene Therapeutics Business Overview
        7.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
        7.12.4 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
        7.12.5 Allogene Therapeutics Key News
    7.13 Celyad
        7.13.1 Celyad Corporate Summary
        7.13.2 Celyad Business Overview
        7.13.3 Celyad CAR-T Therapy in Haematological Malignancy Major Product Offerings
        7.13.4 Celyad CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
        7.13.5 Celyad Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer


List of Tables and Figures
Ask Sample Report to get more details…

NEED Help?

If you need any help or guidance, please feel free to call us.

USA : +1 (661) 636 6162

INDIA : +91 9325802062

or

Write us on : sales@kandjmarketresearch.com